Pfizer, Inc. (NYSE: PFE) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the full approval of Paxlovid, its antiviral pill for Covid-19. The drug currently has emergency use authorization (EUA) for the treatment of mild-to-moderate Covid-19. Albert Bourla, the Chairman and CEO of Pfizer, said, “Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce Paxlovid as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status.
https://www.tipranks.com/news/pfizer-has-big-plans-for-paxlovid?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Jul 2022 até Ago 2022 Click aqui para mais gráficos Pfizer.
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Ago 2021 até Ago 2022 Click aqui para mais gráficos Pfizer.